KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.4K citations

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

David A. Eberhard, Bruce E. Johnson, Lukas C. Amler et al. · Journal of Clinical Oncology · 2005 · 1.5K citations · Full text

K-<i>ras</i>Oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung

Robert J.C. Slebos, R.E. Kibbelaar, Otilia Dalesio et al. · New England Journal of Medicine · 1990 · 809 citations · Full text

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Nathan T. Ihle, Lauren A. Byers, Edward S. Kim et al. · JNCI Journal of the National Cancer Institute · 2012 · 523 citations · Full text